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The poor clinical outcome in pancreatic ductal
adenocarcinoma (PDA) is attributed to intrinsic che-
moresistance and a growth-permissive tumor micro-
environment. Conversion of quiescent to activated
pancreatic stellate cells (PSCs) drives the severe
stromal reaction that characterizes PDA. Here, we
reveal that the vitamin D receptor (VDR) is expressed
in stroma from human pancreatic tumors and that
treatment with the VDR ligand calcipotriol markedly
reduced markers of inflammation and fibrosis in
pancreatitis and human tumor stroma. We show
that VDR acts as a master transcriptional regulator
of PSCs to reprise the quiescent state, resulting in
induced stromal remodeling, increased intratumoral
gemcitabine, reduced tumor volume, and a 57% in-
crease in survival compared to chemotherapy alone.
This work describes a molecular strategy through
which transcriptional reprogramming of tumor
stroma enables chemotherapeutic response and80 Cell 159, 80–93, September 25, 2014 ª2014 Elsevier Inc.suggests vitamin D priming as an adjunct in PDA
therapy.INTRODUCTION
Cancer-associated fibroblast-like cells (CAFs) in the tumor
stromahavebeenshown toexert aprofound influenceon the initi-
ation and progression of human cancer (Bhowmick et al., 2004;
Kalluri and Zeisberg, 2006; Pietras and Ostman, 2010; Ra¨sa¨nen
andVaheri, 2010;Shimodaet al., 2010). Pancreatic ductal adeno-
carcinoma (PDA) in particular is defined by a prominent stromal
compartment, and numerous features ascribed to CAFs promote
pancreatic cancer progression and hinder therapeutic efficacy
(Mahadevan and Von Hoff, 2007). CAFs enhance PDA growth in
allograft models in part via paracrine activation of pro-survival
pathways in tumor cells, and inhibition of tumor-stroma interac-
tions limits tumor progression (Hwang et al., 2008; Ijichi et al.,
2011; Vonlaufen et al., 2008). Further, the dense extracellular
matrix (ECM) associated with PDA obstructs intratumoral vascu-
lature, preventing chemotherapeutic delivery (Olive et al., 2009),
leading tonew ideas toovercome this stromal ‘‘roadblock’’ (Jaco-
betz et al., 2013; Provenzano et al., 2012). Beyond drug delivery,
recent evidence implicates the tumor stroma in innate drug resis-
tance in numerous tumor types (Straussman et al., 2012; Wilson
et al., 2012), and treatment paradigms targeting both neoplastic
cells and stromal components are emerging for PDA (Heinemann
et al., 2012). While these findings suggest that CAFs in the PDA
microenvironment represent a potential therapeutic target, the
tumor-supporting features of pancreatic stellate cells (PSCs),
the predominant fibroblastic cell type in the tumor microenviron-
ment of the pancreas, remain poorly understood.
PSCs are nestin-positive and resident lipid-storing cells of the
pancreas, with an important role in normal ECM turnover (Apte
et al., 1998; Phillips et al., 2003). In health, PSCs are in a quiescent
state, characterized by abundant cytoplasmic lipid droplets rich in
vitamin A and low levels of ECM component production (Apte
et al., 2012). During pancreatic injury, PSCs are activated by
cytokines, growth factors, oxidative or metabolic stress, and
transdifferentiate to a myofibroblast-like cell (Masamune and Shi-
mosegawa, 2009). Activated PSCs lose their cytoplasmic lipid
droplets, express the fibroblast activation marker a-smooth mus-
cle actin (aSMA), acquire proliferative capacity, and synthesize
abundant ECM proteins. Activated PSCs also acquire an expan-
sive secretome which is starkly subdued in the quiescent state
(Wehr et al., 2011). Persistent PSC activation under conditions of
chronic injury results in pathological matrix secretion leading to
fibrosis, creatingaphysical barrier to therapy. Further, a reciprocal
supportive role for activatedPSCsandpancreaticcancercells has
become increasingly appreciated: pancreatic cancer cells pro-
duce mitogenic and fibrogenic factors that promote PSC activa-
tion, such as platelet-derived growth factor (PDGF), transforming
growth factor b (TGF-b), and sonic hedgehog (SHH) (Apte andWil-
son, 2012; Bailey et al., 2008). Reciprocally, activated PSCs pro-
duce PDGF, insulin-like growth factor 1 (IGF1), connective tissue
growth factor (CTGF), and other factors that may promote cancer
cell proliferation, survival, and migration (Apte and Wilson, 2012;
Feig et al., 2012). Tumor-promoting features are largely restricted
to the activated PSC state; the activation process may be revers-
ibleassuggestedby recentwork inhepatic stellatecells (Kisseleva
et al., 2012).However, the cellular factors andmolecular pathways
controlling this process remain elusive.
We hypothesized that pharmacologic means to revert acti-
vated cancer-associated PSCs (CAPSCs) to quiescence would
hinder tumor-stroma crosstalk and tumor growth, resulting in
enhanced clinical efficacy of cancer cell-directed chemotherapy.
We show here that the vitamin D receptor (VDR) acts as a master
genomic suppressor of the PSC activation state. VDR ligand re-
duces fibrosis and inflammation in a murine pancreatitis model
and simultaneously undermines multiple tumor-supporting
signaling pathways in PDA to enhance the efficacy of a coadmi-
nistered chemotoxic agent. These results highlight a potentially
widely applicable strategy to modulate stroma-associated pa-
thologies including inflammation, fibrosis, and cancer.
RESULTS
Identification of Cancer-Associated Gene Signatures
in PSCs
To characterize cancer-associated changes in PSCs, we per-
formed massively parallel sequencing (RNA-sequencing [RNA-seq]) of the PSC transcriptome at various stages of activation.
A comparison of the transcriptomes of preactivated (3-day cul-
ture) and culture-activated (7 day culture) (Omary et al., 2007)
PSCs isolated from healthy mouse pancreas revealed that, dur-
ing activation, PSCs decrease expression of genes implicated in
lipid storage and lipid metabolism, consistent with loss of the
lipid droplet phenotype associated with quiescence (Figure 1A
and Figures S1A–S1C available online). Activation also resulted
in increased expression of a cadre of genes with tumor-support-
ing potential including cytokines, growth factors, ECM compo-
nents, and signaling molecules such as Wnts. Notably, cytokine
induction in the stroma has been shown to promote pancreatic
cancer initiation and progression in a paracrine manner (Fukuda
et al., 2011; Lesina et al., 2011). In addition to the PSC
‘‘activation signature’’ resulting from transdifferentiation in cul-
ture, we identified a PSC ‘‘cancer signature’’ by comparing
the transcriptomes of PSCs isolated from patients with PDA
(CAPSCs) with those from patients undergoing resection for
benign conditions (Figure 1B). These human PSCs were
cultured (and thus culture-activated) for 15 days to achieve
adequate yield and purity. This comparison of activated non-
cancer-associated PSCs to cancer-associated PSCs reveals
changes to the activated phenotype resulting from exposure
to the tumor microenvironment. Both the activation and cancer
signatures include gene classes from a previously identified
stromal signature that predicts poor survival and chemoresist-
ance in PDA (Garrido-Laguna et al., 2011). Lipid storage genes
such as fatty acid binding proteins were downregulated in both
signatures and were accompanied by increased expression of
genes implicated in the cholesterol biosynthesis and uptake
pathway, consistent with an increased proliferative capacity.
Given the hypovascular nature of PDA, particularly within stro-
mal regions, the reciprocal induction of negative angiogenic
regulators and suppression of angiogenic inducers is auspi-
cious (Figure 1C). In particular, we note the induction of throm-
bospondin-1 (Thbs1), a well-described and potent endogenous
inhibitor of angiogenesis (Lawler, 2002). Both gene signatures
include ECM components, cell adhesion molecules, inflamma-
tory mediators, paracrine growth and survival factors, genes
implicated in lipid/cholesterol metabolism, and modulators of
signal transduction.
VDR Regulates the PSC Activation Network
These analyses also revealed that PSCs unexpectedly express
high levels of the vitamin D receptor (VDR), previously thought
not to be expressed in the exocrine pancreas (Zeitz et al.,
2003) (Figures 1D, 1E, S1D, and S1E). Importantly, VDR expres-
sion is maintained in the cancer-associated PSCs (Figure 1F).
We focused on this druggable receptor in light of our previous
work implicating VDR as a critical regulator of the fibrogenic
gene network in closely related hepatic stellate cells (Ding
et al., 2013) and due to the established anti-inflammatory actions
of 1,25(OH)2D3 and its analogs (Cantorna et al., 1996, 1998,
2000; Ma et al., 2006; Nagpal et al., 2005). Here, we used calci-
potriol (Cal), a potent and nonhypercalcemic vitamin D analog to
control VDR induction (Naveh-Many and Silver, 1993). While not
present in any postsurgical CAPSCs, surprisingly, Cal treatment
induced lipid droplet formation in 19/27 primary patient samplesCell 159, 80–93, September 25, 2014 ª2014 Elsevier Inc. 81
Figure 1. Activated and Cancer-Associated PSCs Exhibit a Profibrotic, Proinflammatory Phenotype
(A) Heatmap representing selected genes from RNA-seq analysis of primary mouse PSCs, demonstrating gene categories with altered expression during
activation. Data are represented as log2 fold change, activated (day 7) versus preactivated (day 3), n = 3 per group.
(B) Heatmap representing selected genes from RNA-seq analysis of primary human PSCs, isolated from PDA patients (n = 5) or cancer-free donors (n = 4), and
cultured for 15 days to achieve adequate yield and purity, expressed as log2 fold change PDA versus cancer-free.
(C) Heatmap showing the relative abundance of negative (top) and positive (bottom) regulators of angiogenesis in preactivated and activated primary mouse
PSCs.
(D) Vdr expression in mouse whole-pancreas homogenates and in isolated PSCs, cultured for 3 days to expand and purify, as measured by quantitative RT-PCR
(qRT-PCR).
(legend continued on next page)
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(Figures 2A and S2A) and decreased expression of aSMA
(ACTA2) in 24/27 patient samples (Figure 2B). This strongly sup-
ports the idea that the activation state is controllable in a signal-
dependent fashion. To assess the genome-wide effects of VDR
activation in PSCs, we performed transcriptome analysis of pre-
activated and activated PSCs grown in the presence or absence
of VDR ligand. While Cal treatment affected gene expression in
preactivated PSCs (significantly increased and decreased
expression of 307 and 431 genes, respectively), VDR activation
had a more widespread transcriptional response in activated
PSCs (664 and 1,616 genes with significantly increased and
decreased expression, respectively). Notably, we observed a
Cal-dependent inhibition of the activation and cancer signatures
in PSCs (Figure 2C; Table S1), including suppression of negative
regulators of angiogenesis such as Thbs1 and induction of pos-
itive regulators of angiogenesis like Mmp9 (Bergers et al., 2000)
(Figure 2D). Similar effects of Cal treatment were observed on
selected candidate genes in human CAPSCs (Figure 2E).
Furthermore, these effects were dependent on VDR, as small
interfering RNA (siRNA)-mediated knockdown of the receptor
abrogated Cal-induced expression changes (Figure 2F). To
explain, in part, the broad impact of VDR on the PSC activation
program, we assessed genomic crosstalk between VDR and
the TGF-b/SMAD pathway (Schneider et al., 2001; Yanagisawa
et al., 1999) that we previously demonstrated in hepatic stellate
cells (Ding et al., 2013). Consistent with an inhibitory effect on
TGF-b/SMAD signaling, Cal increased VDR binding while
decreasing SMAD3 binding in the promoter regions of fibrogenic
genes (Figures S2B and S2C). To determine whether VDR activa-
tion decreased PSC activation in vivo, we induced experimental
chronic pancreatitis in wild-type mice using the cholecystokinin
analog cerulein (Willemer et al., 1992) and coadministered Cal
throughout disease progression. Compared to mice receiving
cerulein alone, Cal-treated animals displayed attenuated inflam-
mation and fibrosis, consistent with decreased PSC activation
(Figures S3A and S3B). Expression of activation and cancer
signature genes was decreased in isolated PSCs from mice
treated with Cal compared to controls (Figure 3A). Reductions
were observed on activation signature genes that are of func-
tional significance in the tumor microenvironment, including
ECM components, inflammatory cytokines, and growth factors.
In addition, Acta2 expression, which is associated with cell
motility, trended downward. Further, reduced induction of phos-
pho-Stat3 was observed in Cal-treated mice (Figure 3B), consis-
tent with decreased inflammatory signaling from the stroma.
Notably, Stat3 activation has been established as a mechanistic
link between inflammatory damage and initiation of PDA (Fukuda
et al., 2011; Lesina et al., 2011). Cal treatment during acute
pancreatitis in wild-type mice similarly impaired activation-asso-
ciated changes in PSC gene expression (Figure 3C) and reduced
leukocyte infiltration and fibrosis (Figures 3D and 3E). Strikingly,
pancreata from Vdr/ mice displayed spontaneous periacinar(E) Vdr expression in the indicated pancreatic populations by qRT-PCR (norma
microdissection (LCM); PSCs were isolated by density centrifugation (DC).
(F) Vdr expression in preactivated and activated mouse PSCs (left) and in huma
qRT-PCR (normalized to 36b4, n = 3). Bars indicate the mean; error bars indicat
See also Figure S1.and periductal fibrosis (Figure S3C), further supporting a role
for VDR in opposing PSC activation. Consistent with this
notion, activation-associated changes in PSC gene expression
were augmented in cerulein-induced acute pancreatitis in
Vdr/ mice (Figure 3F) and were accompanied by increased
fibrosis (Figure 3G). Furthermore, Cal treatment of culture-acti-
vated PSCs from Vdr/ mice demonstrated the VDR depen-
dence of the observed gene expression changes (Figure 3H).
Together, these results suggest that VDR acts as a master
genomic regulator of the PSC activation program, and VDR in-
duction by ligand promotes the quiescent PSC state both
in vitro and in vivo.
Stromal VDR Activation Inhibits Tumor-Supportive
Signaling Events
We next assessed the impact of VDR activation in PSCs on
crosstalk to tumor cells. While CAPSCs consistently expressed
VDR and responded to ligand, pancreatic cancer cell lines dis-
played varying VDR expression and typically low VDR activity
(Figures S4A and S4B). This was observed in human PDA
samples as well (Figure S4C). To assess the contribution of
stromal VDR activation on the epithelial compartment, we
examined the effects of CAPSC-derived secreted factors on
the MIAPaCa-2 cell line, which has extremely low VDR expres-
sion and no significant response to VDR ligand (Figures S4A
and S4B). Primary CAPSCs were grown to confluency and
cultured in the presence or absence of Cal for the final 48 hr
of culture. CAPSC-conditioned media (CM) collected from
these cultures was transferred to MIAPaCa-2 cells for 48 hr.
Volcano plot analysis of gene expression in MIAPaCa-2 cells
incubated in CAPSC CM revealed broad changes (center
panel), which were largely abrogated (right panel) when CM
from Cal-treated CAPSCs was used (Figure 4A). CAPSC CM
induced gene expression changes in epithelial cells implicated
in proliferation (Table S2), survival, epithelial-mesenchymal
transition, and chemoresistance. These changes were broadly
inhibited by stromal, but not epithelial, VDR activation (Fig-
ure 4B), though direct antiproliferative and proapoptotic effects
of VDR activation in pancreatic cancer cells have been
reported in other experimental systems (Persons et al., 2010;
Yu et al., 2010). Importantly, this sensitivity to stromal, but
not epithelial, VDR activation was replicated in pancreatic
cancer cell lines with variable VDR expression (Figures 4C–
4G). Of note, stromal VDR activation significantly reduced
CSF2 expression, implicated in pancreatic tumor progression
and evasion of antitumor immunity (Bayne et al., 2012; Py-
layeva-Gupta et al., 2012). Gene expression changes were
accompanied by decreased induction of phospho-STAT3
(Figure 4H) and decreased resistance to chemotherapy
in vitro (Figure 4I). These results demonstrate that VDR activa-
tion in PSCs negatively regulates the tumor-supporting PSC
secretome.lized to 36B4; n = 5). Acini, ducts, and islets were isolated by laser capture
n non-cancer-associated and cancer-associated PSCs (right) determined by
e SD.
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Figure 2. A VDR-Regulated Transcriptional Network Opposes PSC Activation
(A) Representative images of primary human CAPSCs treated with vehicle (DMSO) or 100 nM calcipotriol (Cal) for 48 hr and stained with BODIPY 493/503 for
detection of neutral lipids. Quantification of percent BODIPY-positive area per cell in three patient samples treated with DMSO or Cal appears below, plotted as
the mean + SD. Statistical significance determined by Student’s unpaired t test (*p < 0.05). Scale bar represents 20 mm.
(B) Expression of ACTA2 in 27 primary human CAPSCs treated with vehicle or 100 nM Cal for 48 hr. Values were plotted as DMSO/Cal and normalized to 36B4.
(C and D) Heatmap representing selected genes from RNA-seq analysis of primary mouse PSCs treated with DMSO (D) or Cal (C) and harvested on day 3
(preactivated) or day 7 (activated) of culture after isolation (n = 3). VDR target genes Cyp24a1 and Vdr are shown as controls. See also Table S1. (D) Heatmap
showing the relative abundance of negative (top) and positive (bottom) regulators of angiogenesis in activated primary mouse PSCs cultured in the presence of
vehicle (DMSO) or Cal.
(legend continued on next page)
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VDR Ligand plus Gemcitabine Shows Efficacy
against PDA In Vivo
A principal goal for PSC-targeted therapy is to exploit the inhibi-
tion of tumor-stroma crosstalk to enhance efficacy of a cytotoxic
(or immunologic) agent, which in the case of gemcitabine,
although standard of care, offers minimal (1.5 month) benefit to
PDA patients (Burris et al., 1997). To explore the potential of
vitamin D combination therapy we first explored Cal treatment
in an orthotopic allograft model utilizing immune-competent
hosts (Collisson et al., 2012). The tumor cells for transplantation
were derived from p48-Cre; KrasLSL-G12D/+; p53lox/+ mice
(Bardeesy et al., 2006) and express low levels of Vdr (Figures
S5A and S5B). Two other mouse PDA-derived cell lines demon-
strated low VDR expression and activity as well (Figures S5A and
S5B). This suggests that any observed therapeutic effect would
likely result from host-derived stromal VDR activation, though
some contribution from the epithelial compartment is not
excluded. Although the stromal reaction in transplant models
of PDA is subdued compared to the spontaneous KPC
(KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx-1-Cre) model (Hingorani
et al., 2005; Olive et al., 2009), measurable PSC activation of
Col1a1, Col1a2, and Acta2 was observed in allograft recipients,
accompanied by fibrosis (Figures S5C and S5D). Cal treatment
decreased stromal activation and fibrosis in transplanted mice
(Figure S5E). Although transplant models are responsive to gem-
citabine, we also compared mice treated with gemcitabine to
those treated with a combination of gemcitabine and Cal. Impor-
tantly, in combination therapy recipients, we observed a clear
improvement in gemcitabine responsiveness with respect to
inhibition of proliferation and expression of stromal and epithe-
lial genes from our signatures for PSC activation (Figures S5F
and S5G).
We next tested the efficacy of gemcitabine plus Cal combina-
tion therapy in the KPC model, which recapitulates human PDA
in poor uptake of and response to gemcitabine (Olive et al.,
2009). Combination therapy significantly reduced tumor volume
with transient or sustained reduced tumor growth observed in
70% of mice (Figures 5A and S6A). In agreement with the in-
duction of stromal remodeling, reduced tumor-associated
fibrosis was observed in mice that received combination therapy
compared to controls (Figure 5B). Further, combination-treated
mice demonstrated significantly altered expression of genes
from our stromal and epithelial gene signatures associated
with PSC activation (Figure 5C). The decreased expression of
PSC activation genes and induction of quiescence marker
Fabp4 suggests that the tumor-associated PSCs are shifting
from an activated toward a quiescent state. The observed differ-
ential sensitivity of individual genes to the drug treatment
regimens may be the result of specific perturbations to stro-
mal-tumor paracrine signaling in vivo.(E) Expression levels of selected genes from the PSC activation or cancer sign
representative of three patient samples and are plotted as the mean + SD qRT-P
Statistical significance determined by Student’s unpaired t test (*p < 0.05).
(F) CAPSCs were transfected with siRNA pools against VDR (siVDR) or a non-non
and analyzed by qRT-PCR. Values were normalized to 36B4. Results are represe
significance determined by Student’s unpaired t test (*p < 0.05; n.s. = not signifi
See also Figure S2.Combination therapy also increased intratumoral concentra-
tion and efficacy of gemcitabine (Figures 5D and S6B), with
500% increase in the median concentration of dFdCTP, an
activemetabolite of gemcitabine, inmice that received combina-
tion therapy compared to gemcitabine alone. No drug-induced
changes were seen in the expression levels of the gemcitabine
degrading enzyme cytidine deaminase (Cda), the rate-limiting
deoxycytidine kinase (dCK), or the nucleoside transporter Ent1
(Figure 6A), though allosteric effects are possible. Increased
dFdCTP was accompanied by increased positivity for apoptotic
marker CC3, indicating improved chemotherapeutic efficacy
(Figure 5E). Furthermore, intratumoral vasculature was signi-
ficantly increased by combination therapy, evidenced by in-
creased CD31 positivity and apparent vessel patency (Figures
6B and 6C). While the combination of Cal with gemcitabine
markedly improved therapeutic efficacy, in the absence of gem-
citabine, Cal alone showed no measurable beneficial effects
(data not shown). Importantly, gemcitabine plus Cal combination
therapy significantly prolonged survival of KPC mice compared
to chemotherapy alone, with median survival increased by
57% (median survival: Gem = 14 days, Gem + Cal = 22 days)
(Figure 6D). In addition, in the Cal + Gem arm only, 29% of the
mice were ‘‘long term’’ survivors (>30 days) with an average sur-
vival of 52.8 days.
DISCUSSION
Despite numerous attempts, the 5 year survival rate (6%) for
pancreatic cancer has not changed in decades (Rahib et al.,
2014). In part, this is because treatments targeting tumor cells
have largely failed. The emerging role for tumor stroma as the
‘‘fuel supply-line’’ for cancer offers an opportunity to redirect
the singular focus on the cancer cell itself to the greater tumor
microenvironment (Figure 7). Indeed, by targeting VDR to tran-
scriptionally reprogram the stroma, we simultaneously suppress
inflammatory cytokines and growth factors, enhance angiogen-
esis, increase the efficacy of gemcitabine treatment in PDA and,
most importantly, significantly improve survival.
VDR-directed therapy has a dual benefit as it reduces fibrosis
and inflammation in both acute and chronic murine pancreatitis.
This is significant as pancreatitis lacks any mechanistic-based
therapy, is a seriously disease, and is a known risk factor for
pancreatic cancer. Recently, we have shown that VDR achieves
these effects by blocking TGF-b/SMAD signaling via genomic
competition (Ding et al., 2013). In the acute setting, this could
preclude damaging effects of an unchecked wound healing
response. This balance may be tipped unfavorably by chronic
tissue damage or by vitamin D deficiency, which may explain
in part the inverse correlation between plasma vitamin D levels
or vitamin D intake and pancreatic cancer risk (Skinner et al.,atures in CAPSCs treated with DMSO or 100 nM Cal for 48 hr. Results are
CR was performed in technical triplicate and values were normalized to 36B4.
targeting control (siNT). Cells were treated with DMSO or 100 nM Cal for 48 hr
ntative of three patient samples and are plotted as the mean + SD. Statistical
cant).
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Figure 3. VDR Ligand Modulates PSC Activation In Vivo
(A) Expression levels of selected genes in PSCs isolated from mice injected with cerulein (Cer) or cerulein + Cal for 12 weeks (n = 10). Values were normalized to
36b4 and are plotted as the mean + SD.
(B) Quantification of immunofluorescent staining for phospho-Stat3 (p-Stat3) on frozen sections from wild-type mice treated with cerulein or cerulein + Cal for
12 weeks (n = 5).
(C) Expression levels of selected genes in PSCs isolated from mice injected with Cer or Cer + Cal to induce acute pancreatitis (for details see Extended
Experimental Procedures; n = 5). Values were normalized to 36b4 and are plotted as the mean + SD.
(legend continued on next page)
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2006; Wolpin et al., 2012) and the link between vitamin D defi-
ciency and chronic pancreatitis (Mann et al., 2003).
Our work illustrates that transcriptional remodeling of pancre-
atic tumor stromaviaVDRactivation broadlyweakens the capac-
ity of PSCs to support tumor growth. VDR genomic targets of
importance in PDA include the extracellular matrix (Jacobetz
et al., 2013; Provenzano et al., 2012), the Shh pathway (Olive
et al., 2009), cytokines/chemokines such as IL6 (Fukuda et al.,
2011; Ijichi et al., 2011; Lesina et al., 2011), growth factors such
as CTGF (Aikawa et al., 2006; Neesse et al., 2013) and Cxcl12,
a mediator of the T cell blockade (Ding et al., 2013; Feig et al.,
2012). This gains significance in light of recent work demon-
strating that inhibition of stroma-derived survival factorCTGFpo-
tentiates the antitumor response to gemcitabine (Neesse et al.,
2013) and that CXCL12 inhibition can restore T cell response.
Notably, important differences exist between stromal ablation
and stromal remodeling therapeutic strategies. The notion that
cellular and structural components of a ‘‘normal’’ microenviron-
ment exert tumor-suppressive forces and signals has been dis-
cussed previously (Bissell and Hines, 2011), although this has
not been demonstrated in the pancreas and leaves in question
the potential benefits of reprogrammed stroma. As VDR ligand
pushes activated PSCs toward a more quiescent phenotype, it
is conceivable that remodeled PSCs re-establish a physiologic
and metabolic environment adverse to tumor growth, a benefit
not achievable by stromal ablation. The role of VDR in tissue vital-
ity and resilience is supported by the fact that absence of VDR in
normal stroma is sufficient to promote tissue fibrosis and ahyper-
inflammatory response. This potential benefit of VDR-mediated
stromal remodeling, to restore normal stroma, offers a concep-
tual advantage over stromal depletion that could leave a tissue
without a critical control mechanism.
PDA stroma is believed to limit chemotherapeutic efficacy by
blocking drug delivery, a result of severe hypovascularity attrib-
utable in part to dense extracellular matrix. VDR ligand signifi-
cantly reduced the fibrotic content of the tumor and increased
intratumoral vasculature. We also demonstrate here that acti-
vated PSCs express antiangiogenic factors such as thrombo-
spondin-1, known to contribute to the hypovascularity in other
contexts (Kazerounian et al., 2008). The antiangiogenic subset
of PSC activation signature genes was suppressed by VDR
ligand in vitro and, importantly, combination therapy induced
improvement of tumor vascularity and drug delivery in vivo. Ma-
trix degradation strategies that increase intratumoral blood flow
and gemcitabine delivery have been shown to improve survival
in PDA (Jacobetz et al., 2013; Provenzano et al., 2012). However,
the significance of VDR-mediated stromal remodeling and
improved vascularity with respect to long-term tumor growth(D) Leukocyte recruitment, as measured by CD45-positive cells, in mice with acu
203 field, n = 5).
(E) Fibrosis, as measured by Sirius red staining, in mice with acute pancreatitis (
(F) Expression levels of selected genes in PSCs isolated from Vdr+/+ and Vdr/m
shown; values normalized to B2M.
(G) Sirius red-positive area in Vdr+/+ and Vdr/mice with acute pancreatitis (per 2
(*p < 0.05).
(H) Expression levels of selected genes in PSCs isolated from Vdr+/+ and Vdr/m
determined by Student’s unpaired t test (*p < 0.05; n.s. = not significant).and metastatic potential are currently under investigation.
Indeed, the recent failure of clinical trials exploring the therapeu-
tic potential of Shh pathway inhibition in combination with gem-
citabine in pancreatic cancer bring to light potential limitations of
stromal depletion therapy in the context of current treatment
strategies (Amakye et al., 2013). Conceptually, reprogramming
the tumor stroma and increasing functional vasculature could
create a window for therapeutic delivery as well as heighten
the potential for dissemination of tumor cells through the blood-
stream. While activated stroma is generally considered to
enhance tumor growth, two recent papers suggest that elimi-
nating stroma by targeted deletion results in undifferentiated,
aggressive pancreatic cancer and conclude that activated
stroma is beneficial not harmful (Rhim et al., 2014; Ozdemir
et al., 2014). Our work is not inconsistent with these studies as
quiescent, vitamin A and lipid droplet-positive stromal cells are
a hallmark of healthy tissue and stromal depletion strategies
run the risk of eliminating key stromal components needed for
tissue homeostasis. As we show, addition of Calcipotriol to gem-
citabine treatment enhances survival of KPC mice by 58% while
also generating significant (29%) long term survivors. Thus, in
contrast to stromal depletion, we advocate that stromal reprog-
ramming not only reduces the fuel supply line for the tumor, but it
also restores normal function while allowing for enhanced
chemotherapeutic efficacy and potential T cell response. Thus,
in our view, coupling signal-dependent stromal reprogramming
with tumor-directed cytotoxic and immunologic drugs should
be the goal of new PDA therapies.EXPERIMENTAL PROCEDURES
Cell Lines
The human pancreatic cancer cell lines MIAPaCa-2 (CRL-1420), BxPC-3
(CRL-1687), HPAC (CRL-2119), Panc1 (CRL-1469), and AsPC1 (CRL-1682)
were acquired from ATCC and cultured according to supplier’s instructions.
The mouse pancreatic cancer cell lines p53 2.1.1, p53 4.4, and Ink 2.2 were
derived from PDA inKrasLSL-G12D/+; Trp53lox/+; p48-Cremice or KrasLSL-G12D/+;
Ink4a/Arflox/lox; p48-Cremice (Bardeesy et al., 2006; Collisson et al., 2011) and
cultured as described previously (Collisson et al., 2011, 2012). The spontane-
ously immortalized human pancreatic stellate cell line hPSC was isolated and
established from a pancreatic cancer patient after surgical resection, as previ-
ously described (Mantoni et al., 2011). Primary PSC isolation from resected hu-
man PDAwas performed in accordancewith the Instutitional ReviewBoards of
the Salk Institute for Biological Studies and the University of Pennsylvania.
Description of primary PSC isolation and culture can be found in the Extended
Experimental Procedures.
Animals
KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx-1-Cre (KPC) mice were described previ-
ously (Hingorani et al., 2005) as were Vdr/ mice (Yoshizawa et al., 1997).te pancreatitis (immunofluorescent staining of frozen sections, positive cells in
per 203 field, n = 5).
ice injected with cerulein to induce acute pancreatitis (n = 5). Means + SD are
03 field, n = 5). Statistical significance determined by Student’s unpaired t test
ice after treatment with DMSO or 100 nM Cal for 48 hr. Statistical significance
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Figure 4. Stromal VDR Activation Decreases Protumorigenic Paracrine Signaling
(A) Volcano plots representing gene expression changes detected by RNA-Seq in MIAPaCa-2 cells treated with 100 nM Cal for 48 hr versus media alone (left),
with CAPSC-conditioned media (CM) for 48h versus media alone (middle), or with CM from Cal-treated CAPSC (100nM, 48h) for 48h versus media alone. Blue
indicates significant change; red indicates no significant change.
(B) Heatmap representing selected genes from the RNA-Seq analyses described in (A), plotted as fold change versus media alone (DMEM).
(C–G) The indicated cell lines were incubated with Cal directly, or with CM from CAPSC with or without Cal treatment, as described above. Expression levels of
candidate genes CXCL1, CSF2, and AURKB were determined by qRT-PCR. Values were normalized to 36B4; means + SD are shown. Statistical significance
(legend continued on next page)
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Figure 5. Stromal VDR Activation Shows
Efficacy against Pancreatic Carcinoma
In Vivo when Combined with Gemcitabine
KPCmice were treated for 9 days with gemcitabine
(Gem), calcipotriol (Cal), or Gem + Cal (Gem: n = 4;
Cal: n = 7; Gem + Cal: n = 7 unless otherwise
indicated).
(A) Percent change in tumor volume at study
endpoint, measured by high-resolution ultrasound.
Plots indicate range, median, and quartiles. *p <
0.02; Kruskal-Wallis and Dunn’s nonparametric
comparison test.
(B) Aniline blue-stained collagen fibers were
quantified as positive pixels per 203 field. Plots
indicate range, median, and quartiles. *p < 0.05 by
Mann-Whitney U test.
(C) Gene expression in tumor homogenates was
determined by qRT-PCR. Values were normalized
to 36b4. Bars indicate mean + SD. *p < 0.05 by
Student’s unpaired t test (compared toGem alone).
(D) Intratumoral concentrations of gemcitabine
triphosphate (dFdCTP, measured by LC-MS/MS)
in Gem- and Gem + Cal-treated mice 2 hr after the
final dose of gemcitabine (n = 4 and 7, respec-
tively). Plots indicate range, median, and quartiles.
*p < 0.05 by Mann-Whitney U test.
(E) IHC for cleaved caspase-3 (CC3) was quantified
as %CC3-positive tumor cells per 203 field. Plots
indicate range, median, and quartiles. *p < 0.05 by
Mann-Whitney U test.
See also Figure S4.All animal protocols were reviewed and approved by the Institute of
Animal Care and Use Committee (IACUC) of their respective institutes, and
studies were conducted in compliance with institutional and national
guidelines.
RNA-Seq
Total RNA (human, biological quadruplicates; mouse biological triplicates)
was isolated using Trizol (Invitrogen) and the RNeasy mini kit with on-
column DNase digestion (QIAGEN). For transcriptome studies, PSCs were
treated with vehicle (DMSO) or 100 nM calcipotriol (Tocris) and harvested
at the indicated time points. Sequencing libraries were prepared from
100–500 ng total RNA using the TruSeq RNA Sample Preparation Kit v2
(Illumina). Further details can be found in the Extended Experimental Proce-determined by Student’s unpaired t test (*p < 0.05). Results are shown as replicates with one patient sample a
samples (n = 4), though sample-to-sample variability was noted.
(H) Immunoblot for p-STAT3 from MIAPaCa-2 cells treated for 24 hr with 100 nM Cal, CAPSC CM, Cal + CA
served as a loading control. Values indicate densitometric ratios (p-STAT3/Actin).
(I) Viability of MIAPaCa-2 cells, treated as described above, incubated with the indicated doses of gemcit
CAPSC CM samples and are plotted as the mean ± SD. Statistical significance determined by Student
statistically significant differences in viability between CM and CM (PSC + Cal) samples at the indicated do
See also Figure S3 and Table S2.
Cell 159, 80–93, Sdures. Validation was performed by quantitative
RT-PCR as described in Extended Experimental
Procedures, with primer sequences provided in
Table S3.
Lipid Droplet Accumulation Assay
Primary human CAPSCs, allowed to attach to glass
coverslips overnight, were treated with vehicle
(DMSO) or 100 nM calcipotriol for 48 hr. Washedcells were fixed (10% buffered formalin at room temperature for 15 min),
then stained with 1 mg/ml 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-
diaza-s-indacene (BODIPY 493/503, Molecular Probes) for 1 hr at room
temperature, protected from light. Washed, stained cells were mounted
using Vectastain mounting media (Vector Labs) and fluorescence-visualized
through the GFP filter on a Leica DM5000B microscope and quantified using
ImageJ.
Conditioned Media Experiments
Primary CAPSCs were grown to 100% confluency. Fresh media was added to
the cultures, and at this time, CAPSCs were treated with 100 nM calcipotriol.
After 48 hr, conditioned media was harvested, sterile-filtered through 0.45 mm
pores, and added to pancreatic cancer cells (PCCs) at 50%–60% confluency.nd are representative of results frommultiple patient
PSC CM, or Cal + CAPSC (Cal-treated) CM. Actin
abine for 48 hr. Results are representative of three
’s unpaired t test (*p < 0.05). Asterisks designate
se of gemcitabine.
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Figure 6. VDR Ligand Enhances Delivery and Efficacy of Gemcitabine
KPCmice were treated for 9 days with gemcitabine (Gem), calcipotriol (Cal), or Gem + Cal (Gem: n = 4; Cal: n = 7; Gem +Cal: n = 7 unless otherwise indicated), or
treated with Gem (n = 12) or Gem + Cal (n = 15) until moribund.
(A) Dck, Cda, and Slc29a1/Ent1 gene expression in tumor homogenates determined by qRT-PCR. Values were normalized to 36b4. Bars indicate mean + SD.
(B) IHC for CD31 was quantified as CD31 (NovaRed)-positive area per 403 field. Plots indicate range, median, and quartiles. *p < 0.05 by Mann-Whitney U test.
(C) Representative CD31 IHC from Gem- and Gem + Cal-treated KPC tumors. Arrows indicate a collapsed vessel in a gemcitabine-treated tumor (top), and a
vessel with an apparent lumen in a Gem + Cal-treated tumor (bottom). Scale bar represents 50 mm.
(D) Kaplan-Meier survival analysis for KPC mice treated with Gem or Gem + Cal. p = 0.0186 by Mantel-Cox (log rank) test.
See also Figures S5 and S6.PCCs were treated directly with 100 nM calcipotriol at the onset of conditioned
media incubation. After 48 hr, PCCs were harvested and RNA and protein iso-
lated for analysis. For STAT3 phosphorylation experiments, MIAPaCa-2 cells
were serum starved for 12 hr prior to incubation in serum-free DMEM or
serum-free CM for 24 hr before cell lysis.90 Cell 159, 80–93, September 25, 2014 ª2014 Elsevier Inc.Orthotopic Transplant/Allograft Model
The orthotopic transplant model used here was described previously (Collis-
son et al., 2012). Briefly, 1 3 103 p53 2.1.1 cells were orthotopically injected
into 6- to 8-week-old FVB/n mice in 50%Matrigel. After bioluminescent imag-
ing on day 7, mice were randomized into one of four treatment groups: saline,
Figure 7. Model Depicting a Role for VDR in Signal-Dependent
Stromal Remodeling, Limiting Pancreatic Tumor-Stroma Crosstalk
PSCs progressively acquire tumor-supporting functions during activation, a
process that is driven by pancreatic injury and tumor progression via secreted
factors from the epithelial compartment (and possibly from immune/inflam-
matory cells). VDR activation drives reversion of PSCs to a more quiescent,
less tumor-supportive state. As such, cotreatment of pancreatic tumors with
gemcitabine to target the tumor cells and VDR ligand to deactivate PSCs leads
to an overall decrease in the reciprocal tumor-stroma crosstalk that presents a
major barrier to the delivery and efficacy of gemcitabine alone.calcipotriol (60 mg/kg intraperitoneal [i.p.], QDX20), gemcitabine (20mg/kg i.p.,
Q3DX4), or calcipotriol + gemcitabine. For combination-treated mice, calcipo-
triol treatment began on day 7 and gemcitabine treatment began on day 14.
Mice were euthanized on day 26 or when distressed, and pancreata were har-
vested, sliced, and flash frozen in liquid nitrogen or immediately fixed in
formalin.
KPC Study Design
KPC mice with pancreatic ductal adenocarcinoma were enrolled in the study
based on tumor size, as described previously (Olive et al., 2009). For the exper-
iments in Figures 5 and 6, enrollment was restricted to mice with tumors of a
mean diameter between 6 and 9 mm, as determined by high resolution ultra-
sound imaging. Suitable mice were assigned to a treatment group: gemcita-
bine, calcipotriol, or gemcitabine and calcipotriol combination. Gemcitabine
was administered as a saline solution at 100mg/kg by intraperitoneal injection,
once every 3 days; when appropriate, a final dosewas given 2 hr prior to eutha-
nasia. Calcipotriol was administered as a saline solution daily at 60 mg/kg by
intraperitoneal injection. Cal was administered daily for the 9 day regimen
and administered every 3 days (injected with gemcitabine) for the survival
study. Mice were euthanized after 9 days of treatment or at the onset of clinical
signs such as abdominal ascites, severe cachexia, significant weight loss, or
inactivity. Tumors were imaged by high resolution ultrasound up to twice dur-
ing the 9 day treatment study.
Imaging and Quantification of KPC Tumors
High resolution ultrasound imaging of mouse pancreas was carried out using
a Vevo 770 system with a 35 MHz RMV scanhead (Visual Sonics) as
described previously (Dowell and Tofts, 2007). Serial 3D images were
collected at 0.25 mm intervals. Tumors were outlined on each 2D image and
reconstructed to measure the 3D volume using the integrated Vevo 770 soft-
ware package.Quantification of Intratumoral dFdC, dFdU, and dFdCTP by Liquid
Chromatography-Tandem Mass Spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was per-
formed as described by Bapiro et al. (2011). Further details can be found in
the Extended Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the RNA-Seq data is
GSE43770.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and three tables and can be found with this article online at http://
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